Intensity Therapeutics Provides Business Update Reflecting P

FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024
SHELTON, Conn., Jan. 3, 2024...

Related Keywords

Canada , Dublin , Ireland , United States , Ottawa , Ontario , Merck Sharpe Dohme , Jonathan Nugent , David Rosen , Lewish Bender , Bristol Myers Squibb , Christian Frederick Meyer , Company Nasdaq , Ottawa Hospital Research Institute , Office Of Orphan Products Development , Drug Administration , Prnewswire Intensity Therapeutics Inc , Ontario Institute Of Cancer Research , Companya Study May , Intensity Therapeutics Inc , Investigational New Drug , New Drug Application , Study May Proceed , Chief Executive Officer , Connective Tissue Oncology , Assistant Professor , Sidney Kimmel Cancer Center , Johns Hopkins University , Orphan Products Development , Merck Sharpe , Ontario Institute , Cancer Research , Relations Contact , Royal Marsden Hospital Index , Markets ,